BWXT vs EFX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BWXT exhibits exceptional operational health with a Piotroski F-Score of 8/9 and strong growth metrics, but it is currently trading at a severe valuation premium. While earnings growth (31.1% YoY) and ROE (28.52%) are impressive, the current price of $223.15 far exceeds both the Graham Number ($32.91) and the growth-based Intrinsic Value ($105.31). The company is fundamentally a 'strong' business trapped in an 'expensive' stock, further complicated by bearish insider selling and a weak technical trend.
EFX presents a dichotomy between strong operational growth and deteriorating market sentiment. While the Piotroski F-Score of 6/9 indicates stable financial health and the company maintains impressive YoY earnings growth of 34%, the technical trend is severely bearish (0/100) with the stock trading near its 52-week low. The current price of $172.47 is closely aligned with the growth-based intrinsic value ($167.26) but significantly exceeds the defensive Graham Number ($69.68). Liquidity concerns are evident in the low current ratio (0.61), and aggressive insider selling by the CEO and other officers adds to the bearish outlook despite a 'Buy' analyst consensus.
Compare Another Pair
Related Comparisons
BWXT vs EFX: Head-to-Head Comparison
This page compares BWX Technologies, Inc. (BWXT) and Equifax Inc. (EFX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.